clinical trial · NCT06859788
SPI-1005 for the Treatment of Meniere's Disease (Open Label)
Sound Pharmaceuticals, Incorporated·phase3·recruiting·n = 200
Meniere's DiseaseMénière's DiseaseEbselen
brief summary
Study of the safety of open-label SPI-1005 400 mg BID treatment in adults with Meniere's Disease (MD) for 6 or 12 months to support chronic or chronic intermittent use.
started
Oct 29, 2025
primary completion
Dec 1, 2026
completion
Dec 1, 2026
last updated
Dec 26, 2025
official title
Open-Label Study of SPI-1005 for the Treatment of Meniere's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol